Clonal differences underlie variable responses to sequential and prolonged treatment

Cancer cells exhibit dramatic differences in gene expression at the single-cell level which can predict whether they become resistant to treatment. Treatment perpetuates this heterogeneity, resulting in a diversity of cell states among resistant clones. However, it remains unclear whether these differences lead to distinct responses when another treatment is applied or the same treatment is continued. In this study, we combined single-cell RNA-sequencing with barcoding to track resistant clones through prolonged and sequential treatments. We found that cells within the same clone have similar gene expression states after multiple rounds of treatment. Moreover, we demonstrated that individual clones have distinct and differing fates, including growth, survival, or death, when subjected to a second treatment or when the first treatment is continued. By identifying gene expression states that predict clone survival, this work provides a foundation for selecting optimal therapies that target the most aggressive resistant clones within a tumor.

[1]  Sydney M. Shaffer,et al.  Disrupting cellular memory to overcome drug resistance , 2022, bioRxiv.

[2]  Gustavo S. França,et al.  Drug-induced adaptation along a resistance continuum in cancer cells , 2022, bioRxiv.

[3]  A. Marusyk,et al.  Integrating mutational and nonmutational mechanisms of acquired therapy resistance within the Darwinian paradigm. , 2022, Trends in cancer.

[4]  A. Raj,et al.  Pre-determined diversity in resistant fates emerges from homogenous cells after anti-cancer drug treatment , 2021, bioRxiv.

[5]  Jun Yao,et al.  IL-6 promotes drug resistance through formation of polyploid giant cancer cells and stromal fibroblast reprogramming , 2021, Oncogenesis.

[6]  Xiaochen Bo,et al.  clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.

[7]  R. Mathijssen,et al.  Cross-resistance and drug sequence in prostate cancer. , 2021, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[8]  Raphael Gottardo,et al.  Integrated analysis of multimodal single-cell data , 2020, Cell.

[9]  S. Dawson,et al.  Non-genetic mechanisms of therapeutic resistance in cancer , 2020, Nature Reviews Cancer.

[10]  S. Rose-John Interleukin-6 signalling in health and disease , 2020, F1000Research.

[11]  G. Mills,et al.  Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma , 2020, Clinical Cancer Research.

[12]  P. Rutkowski,et al.  Targeted Therapy in Melanoma and Mechanisms of Resistance , 2020, International journal of molecular sciences.

[13]  Jacob G. Scott,et al.  Resistance to targeted therapies as a multifactorial, gradual adaptation to inhibitor specific selective pressures , 2020, Nature Communications.

[14]  Sydney M. Shaffer,et al.  Variability within rare cell states enables multiple paths towards drug resistance , 2020, Nature Biotechnology.

[15]  Younan Chen,et al.  Transcripts 202 and 205 of IL-6 confer resistance to Vemurafenib by reactivating the MAPK pathway in BRAF(V600E) mutant melanoma cells. , 2020, Experimental cell research.

[16]  Gennady Korotkevich,et al.  Fast gene set enrichment analysis , 2019, bioRxiv.

[17]  C. Cho,et al.  Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy , 2019, Front. Oncol..

[18]  Tengyu Ko,et al.  Genome‐wide screening identifies novel genes and biological processes implicated in cisplatin resistance , 2019, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[19]  A. Sartore-Bianchi,et al.  Treatment sequencing in metastatic colorectal cancer. , 2019, European journal of cancer.

[20]  J. Simon,et al.  Induced cross-resistance of BRAFV600E melanoma cells to standard chemotherapeutic dacarbazine after chronic PLX4032 treatment , 2019, Scientific Reports.

[21]  M. Yousefi,et al.  The significant role of interleukin-6 and its signaling pathway in the immunopathogenesis and treatment of breast cancer. , 2018, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[22]  Samantha A. Morris,et al.  Single-cell mapping of lineage and identity in direct reprogramming , 2018, Nature.

[23]  Allon M. Klein,et al.  Lineage tracing on transcriptional landscapes links state to fate during differentiation , 2018, Science.

[24]  Sydney M. Shaffer,et al.  Memory Sequencing Reveals Heritable Single-Cell Gene Expression Programs Associated with Distinct Cellular Behaviors , 2018, Cell.

[25]  Geoff S. Higgins,et al.  Oxidative Phosphorylation as an Emerging Target in Cancer Therapy , 2018, Clinical Cancer Research.

[26]  Sydney M. Shaffer,et al.  Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance , 2017, Nature.

[27]  N. McGranahan,et al.  Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future , 2017, Cell.

[28]  Wolfgang Weninger,et al.  Cell Cycle Phase-Specific Drug Resistance as an Escape Mechanism of Melanoma Cells. , 2016, The Journal of investigative dermatology.

[29]  N. Dhomen,et al.  Application of Sequencing, Liquid Biopsies, and Patient-Derived Xenografts for Personalized Medicine in Melanoma. , 2016, Cancer discovery.

[30]  Shuiping Gao,et al.  Down-Regulation of NDUFB9 Promotes Breast Cancer Cell Proliferation, Metastasis by Mediating Mitochondrial Metabolism , 2015, PloS one.

[31]  P. Rutkowski,et al.  Trametinib: a MEK inhibitor for management of metastatic melanoma , 2015, OncoTargets and therapy.

[32]  V. Sondak,et al.  Fibronectin induction abrogates the BRAF inhibitor response of BRAF V600E/PTEN-null melanoma cells , 2015, Oncogene.

[33]  H P Soyer,et al.  A stress-induced early innate response causes multidrug tolerance in melanoma , 2014, Oncogene.

[34]  R. Hay,et al.  E3 ubiquitin ligase HOIP attenuates apoptotic cell death induced by cisplatin. , 2014, Cancer research.

[35]  O. Sartor,et al.  Treatment sequencing in metastatic castrate-resistant prostate cancer , 2014, Asian journal of andrology.

[36]  Christopher J. Ott,et al.  An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia , 2014, Nature Genetics.

[37]  D. Mukherji,et al.  Sequencing of treatment in metastatic colorectal cancer: where to fit the target. , 2014, World journal of gastroenterology.

[38]  R. Dummer,et al.  Hypoxia contributes to melanoma heterogeneity by triggering HIF1α-dependent phenotype switching. , 2013, The Journal of investigative dermatology.

[39]  P. Gimotty,et al.  Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. , 2013, Cancer cell.

[40]  G. Long,et al.  Dabrafenib and its potential for the treatment of metastatic melanoma , 2012, Drug design, development and therapy.

[41]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[42]  Kevin W Eliceiri,et al.  NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.

[43]  K. Pienta,et al.  Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer , 2012, Molecular Cancer Research.

[44]  P. Yotnda,et al.  Induction and testing of hypoxia in cell culture. , 2011, Journal of visualized experiments : JoVE.

[45]  Jian Wu,et al.  Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells. , 2011, Cytokine.

[46]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[47]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[48]  P. Sorger,et al.  Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis , 2009, Nature.

[49]  N. Pavlakis,et al.  Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review. , 2007, Cancer treatment reviews.

[50]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[51]  D. Mottet,et al.  CoCl2, a Chemical Inducer of Hypoxia‐Inducible Factor‐1, and Hypoxia Reduce Apoptotic Cell Death in Hepatoma Cell Line HepG2 , 2002, Annals of the New York Academy of Sciences.

[52]  A. Fojo,et al.  Multidrug resistance in ovarian cancer , 1987, Cancer.

[53]  S. Lippard,et al.  Structural aspects of platinum anticancer drug interactions with DNA , 1987 .

[54]  P. Nowell The clonal evolution of tumor cell populations. , 1976, Science.

[55]  R. Sullivan,et al.  Sequencing Treatment in BRAFV600 Mutant Melanoma: Anti-PD-1 Before and After BRAF Inhibition , 2017, Journal of immunotherapy.

[56]  J. Mesirov,et al.  The Molecular Signatures Database (MSigDB) hallmark gene set collection. , 2015, Cell systems.